Financial Times writer Alex Bilmes attended a £379 Allen Carr Easyway session at the company's Raynes Park headquarters, joining 11 other smokers seeking to quit after decades of addiction. The organisation claims 50 million successful quitters globally, though independent verification remains elusive. Bilmes, who smoked an estimated 250,000 cigarettes over 35 years, previously switched to Lost Mary disposable vapes in 2022 — a Chinese brand now dominating the UK convenience store shelf — only to trade one nicotine dependency for another.

The UK cessation landscape is shifting. A 2025 UCL study found just 29% of British smokers attempting to quit succeed, while the NHS continues endorsing vaping as a harm-reduction tool despite long-term health uncertainties. The service positions vaping as carrying a "small fraction of the risks of smoking," though critics note the evidence base remains thin. Half of all regular smokers will die from their habit, per NHS data, creating a persistent addressable market for cessation products and programmes.

Allen Carr's group-therapy model — tea, biscuits, and a transparent bin for surrendered devices — represents a low-overhead, high-margin service business. With no pharmaceutical IP to protect, its value lies in brand trust and repeat referrals. Meanwhile, the vaping supply chain, led by Chinese manufacturers like Lost Mary and Vuse (owned by British American Tobacco), captures the recurring revenue stream the NHS effectively subsidises through cessation referrals.